Dr. Ron’s Research Review – July 28, 2010

This week’s research review focuses on prolactin, vitamin B6 and Vitex.

Pyridoxal phosphate inhibits pituitary cell proliferation and hormone secretion (Ren and Melmed 2006)

Vitex agnus castus might enrich the pharmacological armamentarium for medical treatment of prolactinoma (Tamagno, Burlacu et al. 2007)

Are changes of prolactin levels the effectors of vitex agnus castus beneficial effects on the pre-menstrual syndrome? (Tamagno 2009)

Vitex agnus-castus. Monograph (2009)

Here are three other articles you may be interested in.

Galantamine for CFS (Turan, Izgi et al. 2009)

Vinegar ingestion at bedtime moderates waking glucose concentrations in adults with well-controlled type 2 diabetes (White and Johnston 2007)

Vitamin A – Tolerance Extends Longevity

Longevity Medicine Review Link

In the news:

Drastic HCG Diet making comeback, Seattle Times, July 18, 2010 Link

Dr. Ron


Articles

The Effects of Galantamine Hydrobromide Treatment on Dehydroepiandrosterone Sulfate and Cortisol Levels in Patients with Chronic Fatigue Syndrome

            (Turan, Izgi et al. 2009) Download

OBJECTIVE: Mental fatigue, cognitive disorders, and sleep disturbances seen in chronic fatigue syndrome (CFS) may be attributed to cholinergic deficit. A functional deficiency of cholinergic neurotransmission may cause the hypothalamic-pituitary-adrenal axis hypoactivity seen in CFS. Therefore, we investigated the alterations in stress hormones such as cortisol and dehydroepiandrosterone sulfate (DHEAS) in CFS patients before and after 4-week administration of galantamine hydrobromide, a selective acetylcholinesterase inhibitor, and aimed to investigate whether there are any relationships between the probable hormonal changes and cholinergic treatment. METHODS: Basal levels of cortisol and DHEAS were measured in 29 untreated CFS patients who were diagnosed according to Centers for Disease Control (CDC) criteria and in 20 healthy controls. In the patient group, four weeks after 8 mg/d galantamine hydrobromide treatment, cortisol and DHEAS levels were measured again. After the treatment 22 patients who stayed in study were divided into two subgroups as responders and nonresponders according to the reduction in their Newcastle Research Group ME/CFS Score Card (NRG) scores. RESULTS: Important findings of this study are lower pre-and post-treatment cortisol levels and in all CFS patients compared to controls (F=4.129, p=0.049; F=4.803, p=0.035, respectively); higher basal DHEAS values and higher DHEAS/cortisol molar ratios which were normalized following four weeks' treatment with 8 mg/d galantamine hydrobromide in the treatment-respondent group (F=5.382, p=0.029; F=5.722, p=0.025, respectively). CONCLUSION: The findings of the decrease in basal DHEAS levels and DHEAS/cortisol molar ratios normalizing with galantamine treatment may give some support to the cholinergic deficit hypothesis in CFS.

Vinegar ingestion at bedtime moderates waking glucose concentrations in adults with well-controlled type 2 diabetes

            (White and Johnston 2007) Download


Pyridoxal phosphate inhibits pituitary cell proliferation and hormone secretion

            (Ren and Melmed 2006) Download

Pyridoxal phosphate (PLP), a bioactive form of pyridoxine, dose-dependently (10-1000 microm) inhibited cell proliferation in rat pituitary MMQ and GH3 cells and in mouse AtT-20 cells. After 4 d, MMQ cell numbers were reduced by up to 81%, GH3 cell numbers were reduced by up to 64% (P < 0.05), and AtT-20 cell numbers were reduced by up to 90%. Cell proliferation rates recovered and dose-dependently reverted to control levels after PLP withdrawal. After 4 d, PLP (400 and 1000 microm) decreased [3H]thymidine incorporation by up to 71% (P < 0.05). PLP (400-1000 microm) reduced GH3 cell GH and prolactin secretion and AtT-20 cell ACTH secretion (adjusted for cell number) by approximately 70% after 2 d. The 100 microm PLP also inhibited prolactin secretion (65%, P < 0.05) in primary rat pituitary cells treated for 2 d. PLP decreased the percentage of AtT-20 and GH3 cells in S phase and increased those in G0-G1 phase. Furthermore, PLP induced AtT-20 and GH3 cell apoptosis (28 vs. 6, P < 0.05; 26 vs. 3, P < 0.05, respectively) and dose-dependently reduced content of the antiapoptosis gene Bcl-2. These results indicate that pharmacological doses of PLP inhibit pituitary cell proliferation and hormone secretion, in part mediated through PLP-induced cell-cycle arrest and apoptosis. Pyridoxine may therefore be appropriate for testing as a relatively safe drug for adjuvant treatment of hormone-secreting pituitary adenomas.

Vitex agnus castus might enrich the pharmacological armamentarium for medical treatment of prolactinoma

            (Tamagno, Burlacu et al. 2007) Download

Are changes of prolactin levels the effectors of vitex agnus castus beneficial effects on the pre-menstrual syndrome?

            (Tamagno 2009) Download

Vitex agnus-castus. Monograph

            (2009) Download


References

(2009). "Vitex agnus-castus. Monograph." Altern Med Rev 14(1): 67-71.

Ren, S. G. and S. Melmed (2006). "Pyridoxal phosphate inhibits pituitary cell proliferation and hormone secretion." Endocrinology 147(8): 3936-42.

Tamagno, G. (2009). "Are changes of prolactin levels the effectors of vitex agnus castus beneficial effects on the pre-menstrual syndrome?" Maturitas 63(4): 369.

Tamagno, G., M. C. Burlacu, et al. (2007). "Vitex agnus castus might enrich the pharmacological armamentarium for medical treatment of prolactinoma." Eur J Obstet Gynecol Reprod Biol 135(1): 139-40.

Turan, T., H. B. Izgi, et al. (2009). "The Effects of Galantamine Hydrobromide Treatment on Dehydroepiandrosterone Sulfate and Cortisol Levels in Patients with Chronic Fatigue Syndrome." Psychiatry Investig 6(3): 204-210.

White, A. M. and C. S. Johnston (2007). "Vinegar ingestion at bedtime moderates waking glucose concentrations in adults with well-controlled type 2 diabetes." Diabetes Care 30(11): 2814-5.